logo
  

Honda Motor FY Profit Declines; Sales Revenue Up 16.2%

Honda Motor Co. Ltd (HMC) reported that its fiscal year profit attributable to owners of the parent declined to 695.3 billion yen from 707.1 billion yen, previous year. Earnings per share was 409.87 yen compared to 411.09 yen.

For the fiscal year ended March 31, 2023, sales revenue increased to 16.9 trillion yen from 14.5 trillion yen. Consolidated sales revenue increased by 16.2%, due mainly to increased sales revenue in Motorcycle business as well as positive foreign currency translation effects.

Consolidated cash and cash equivalents on March 31, 2023 increased by 128.0 billion yen from March 31, 2022, to 3.80 trillion yen.

For the fiscal year ending March 31, 2024, the company expects: earnings per share of 489.41 yen; and sales revenue of 18.2 trillion yen.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT